Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial | Zendy

Stephen B. Hanauer | Zendy; William J. Sandborn | Zendy; Christian Dallaire | Zendy; André Archambault | Zendy; Bruce Yacyshyn | Zendy; Chyon Yeh | Zendy; Nancy Smith-Hall | Zendy

Open Access

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Author(s) -

Stephen B. Hanauer,

William J. Sandborn,

Christian Dallaire,

André Archambault,

Bruce Yacyshyn,

Chyon Yeh,

Nancy Smith-Hall

Publication year - 2007

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2007/862917

Subject(s) - medicine , ulcerative colitis , adverse effect , gastroenterology , clinical endpoint , randomized controlled trial , subgroup analysis , clinical trial , oral administration , intention to treat analysis , confidence interval , disease

Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC and in the subgroup with moderate disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research